Phase 1
The surprising disclosure was outlined in a November 2017 letter from the FDA.
After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.
MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.
The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
The success has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million.
The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.
PRESS RELEASES